Recently, the research community has had a real-world look at reasons for improving vaccine responses to emerging RNA viruses. Here, a vaccine non-specialist suggests how this might be done. I propose two alternative options and compare the primary alternative option with current practice. The basis of comparison is feasibility in achieving what we need: a safe, mass-produced, emerging virus-targeted vaccine on 2-4 week notice. The primary option is the following. (1) Start with a platform based on live viruses that infect bacteria, but not humans (bacteriophages, or phages). (2) Isolate phages (to be called pathogen homologs) that resemble and provide antigenic context for membrane-covered, pathogenic RNA viruses; coronavirus-phage homologs will probably be found if the search is correctly done. (3) Upon isolating a viral pathogen, evolve its phage homolog to bind antibodies neutralizing for the viral pathogen. Vaccinate with the evolved phage homolog by generating a local, non-hazardous infection with the phage host and then curing the infection by propagating the phage in the artificially infecting bacterial host. I discuss how this alternative option has the potential to provide what is needed after appropriate platforms are built.

中文翻译：

---

优化抗病毒疫苗反应：非专家的意见。

最近，研究团体对改善对新兴RNA病毒的疫苗反应的原因进行了实际研究。在这里，一位非疫苗专家建议如何做到这一点。我提出了两个替代方案，并将主要替代方案与当前实践进行了比较。比较的基础是实现我们所需的可行性：在2-4周内通知的安全，批量生产，新兴的针对病毒的疫苗。主要选项如下。（1）从基于感染细菌而不感染人类（噬菌体或噬菌体）的活病毒的平台开始。（2）分离类似于噬菌体的噬菌体（称为病原体同源物），并为被膜覆盖的致病RNA病毒提供抗原背景；如果正确完成搜索，可能会找到冠状病毒噬菌体同源物。（3）分离出病毒病原体后，进化其噬菌体同源物以结合对病毒病原体中和的抗体。通过用噬菌体宿主产生局部无害感染，然后通过在人工感染的细菌宿主中传播噬菌体来治愈感染，从而对进化的噬菌体同源物进行疫苗接种。我将讨论在构建适当的平台后，该替代选项如何能够提供所需的内容。